New drug may extend women's fertility by six years

Scientists have identified a drug that extends egg viability in worms and could theoretically extend women's fertility by three to six years.

"As early as the mid-30s, women start to experience declines in fertility, increased rates of miscarriage and maternal age-related birth defects," said Coleen Murphy from the Princeton University in the US.

"All of these problems are thought to be caused by declining egg quality, rather than a lack of eggs," said Murphy.

The researchers used a microscopic worm, Caenorhabditis elegans (C elegans), to study longevity.

For the study, published in the journal Current Biology, they investigated downregulated group of proteins, cathepsin B proteases, that are rare in high-quality eggs and more common in eggs that have begun degrading with age.

The existence of drugs that block these exact proteins provided an opportunity to test their effects.

Another experiment that knocked out the cathepsin B genes entirely succeeded in extending worms fertility by about 10 percent.

"If applied to humans, it could be a three- to six-year extension of your reproductive period," said Nicole Templeman from Princeton University.

Reproductive decline is a hallmark of aging, but despite its prevalence, interventions to slow the loss of reproductive capacity are lacking, the researchers said.

(This story has not been edited by Business Standard staff and is auto-generated from a syndicated feed.)

Dear Reader,


Business Standard has always strived hard to provide up-to-date information and commentary on developments that are of interest to you and have wider political and economic implications for the country and the world. Your encouragement and constant feedback on how to improve our offering have only made our resolve and commitment to these ideals stronger. Even during these difficult times arising out of Covid-19, we continue to remain committed to keeping you informed and updated with credible news, authoritative views and incisive commentary on topical issues of relevance.

We, however, have a request.

As we battle the economic impact of the pandemic, we need your support even more, so that we can continue to offer you more quality content. Our subscription model has seen an encouraging response from many of you, who have subscribed to our online content. More subscription to our online content can only help us achieve the goals of offering you even better and more relevant content. We believe in free, fair and credible journalism. Your support through more subscriptions can help us practise the journalism to which we are committed.

Support quality journalism and subscribe to Business Standard.

Digital Editor

Business Standard is now on Telegram.
For insightful reports and views on business, markets, politics and other issues, subscribe to our official Telegram channel